Our Flynn Gold Ltd share price forecast data is based on consensus analyst prediction, covering public companies earnings per share and revenue. Assess the Flynn Gold share price predictions. View ...

Our Cobalt Blue Holdings Ltd share price forecast data is based on consensus analyst prediction, covering public companies earnings per share and revenue. Assess the Cobalt Blue share price ...

Investing.com -- Shares of Clearwater Paper Corp . (NYSE:CLW) surged 15% following reports that Brazil's Suzano SA is considering a takeover bid for the company. According to Bloomberg, Suzano is ...

Investing.com -- TD Cowen analysts upgraded BlackBerry (NYSE:BB) shares on Friday after the cybersecurity software firm delivered solid financial results for the fiscal third quarter a day earlier.

Investing.com -- US stock futures fell Friday as the threat of a US government shutdown increased, and as investors awaited the release of key inflation data. Here are some of the biggest premarket US ...

Investing.com -- Shares of Occidental Petroleum (NYSE:OXY), Sirius XM Holdings (NASDAQ:SIRI), and VeriSign (NASDAQ:VRSN) saw an uptick in the trading session following news of Berkshire Hathaway (NYSE ...

Investing.com -- President-elect Donald Trump warned that the European Union (EU) must significantly increase its purchases of American oil and gas or face tariffs on European imports. “I told the ...

Investing.com -- Bitcoin's value plummeted approximately 9% on Friday, as the cryptocurrency market experienced a sharp sell-off, possibly reflecting a broader investor retreat from risk assets. The ...

Investing.com -- Former Nissan (OTC:NSANY) Motor Co. chairman, Carlos Ghosn, has commented on the potential deal between ...

Investing.com -- Shares of Novo Nordisk (NYSE:NVO) A/S, the Danish pharmaceutical company, experienced a significant drop following the release of less than anticipated results from a study of its ...

Investing.com -- Shares of Novo Nordisk (NYSE:NVO) plummeted over 19% in premarket trading Friday after the results from its phase 3 trial of CagriSema, its next-generation obesity drug, disappointed.